| 心房颤动的上游治疗新进展 |
| |
| 引用本文： | 任启伍,木胡牙提.心房颤动的上游治疗新进展[J].心血管病学进展,2014(1):91-94. |
| |
| 作者姓名： | 任启伍 木胡牙提 |
| |
| 作者单位： | 新疆医科大学第一附属医院综合心脏内科,新疆乌鲁木齐830054 |
| |
| 摘 要： | 心房颤动是最常见的持续性心律失常之一，目前一致认为心房颤动是发病率、病死率都很高的疾病之一。心房颤动的上游治疗受到重视，上游治疗通常包括血管紧张素转换酶抑制剂、血管紧张素受体拮抗剂、醛固酮拮抗剂、他汀类和多聚不饱和脂肪酸（Polyunsaturated fatty acid，PuFA）。这些非抗心律失常药物的抗心律失常作用对心房颤动的一、二级预防可起到一定的作用。
|
| 关 键 词： | 心房颤动 上游治疗 新进展 |
New Research Progress in Upstream Treatment of Atrial Fibrillation |
| |
| Institution: | REN Qiwu,MU Huyati (Comprehensive Cardiac Department of Internal Medicine, The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830054, Xinjiang , China) |
| |
| Abstract: | Atrial fibrillation （AF） is one of the most common arrhythmia, and the current consensus is that AF is one of diseases with high morbidity and mortality. The valued upstream treatment of AF generally consists of drugs as angiotensin converting enzyme inhibitors, an giotensin receptor blockers,aldosterone antagonists,statins and polyunsaturated fatty acid. Antiarrhythmic effects of these non-antiarrhythmic drugs play a certain primary and secondary prevention role for AF. |
| |
| Keywords: | atrial fibrillation upstream treatment new progress |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
